

OTC Pink Basic Disclosure Guidelines

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

Therapy Cells, Inc - name effective from 05/20/2011
Diamond Information Institute, Inc

2) Address of the issuer's principal executive offices

Company Headquarters
Address 1: 500 Hazelwood Road
Address 2: Venice
Address 3: Florida 34293
Phone: +44 1732 460224
Email: info@therapycells.com
Website(s): _____

IR Contact
Address 1: None
Address 2: _____
Address 3: _____
Phone: _____
Email: _____
Website(s): _____

3) Security Information

Trading Symbol: TCEL
Exact title and class of securities outstanding: Common shares and Preferred shares
CUSIP: 88337C102
Par or Stated Value: Common shares par is \$0.0001 and Preferred shares par is \$0.0001
Total shares authorized: Common shares 500,000,000; Preferred shares 100,000,000 as of:
06/30/2014
Total shares outstanding: Common shares 479,741,545; Preferred shares 2,793,757 as of:
06/30/2014

Transfer Agent
Name: Action Stock Transfer Corp
Address 1: 7069 S. Highland Dr, Ste 300
Address 2: Salt Lake City
Address 3: Utah 84121
Phone: 801-274-1088

Is the Transfer Agent registered under the Exchange Act?* Yes: ☒ No: ☐

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

All offerings over the last two years have been private and related to Preference Stock conversions, redemption of Convertible Loan notes or were issued for services supplied to the Company, under Section 3(a)(9) and Section 4(1) of the Securities Act of 1933, as amended, and Rule 144.

B. Any jurisdictions where the offering was registered or qualified;

None

C. The number of shares offered;

See Note D

D. The number of shares sold;

Date	Offered	Sold/Redeemed	Price	Paid	Description of transactions
01-Jan-12	1,037,359	1,037,359	\$0.000000	\$0	Brought forward
28-Mar-12	76,260,000	76,260,000	\$0.000100	\$7,626	Conversion of 76,260 Series E Preferred stock
28-Feb-13	12,300,000	12,300,000	\$0.001000	\$12,300	Redemption of \$12,300 of Convertible Notes
20-Jun-13	2,000,000	2,000,000	\$0.001000	\$2,000	Redemption of \$2,000 of Convertible Notes
25-Jun-13	2,000,000	2,000,000	\$0.001000	\$2,000	Redemption of \$2,000 of Convertible Notes
09-Aug-13	2,200,000	2,200,000	\$0.001000	\$2,200	Redemption of \$2,200 of Convertible Notes
13-Aug-13	750,000	750,000	\$0.001000	\$750	Payment of \$750 for services
16-Aug-13	750,000	750,000	\$0.001000	\$750	Payment of \$750 for services
03-Sep-13	8,250,000	8,250,000	\$0.001000	\$8,250	Redemption of \$8,250 of Convertible Notes
10-Sep-13	5,000,000	5,000,000	\$0.001000	\$5,000	Redemption of \$5,000 of Convertible Notes
11-Feb-14	6,240,000	6,240,000	\$0.000100	\$624	Redemption of \$624 of Convertible Notes
14-Feb-14	6,563,800	6,563,800	\$0.000100	\$656	Redemption of \$656 of Convertible Notes
25-Feb-14	6,907,680	6,907,680	\$0.000100	\$691	Redemption of \$691 of Convertible Notes
05-Mar-14	7,260,000	7,260,000	\$0.000100	\$726	Redemption of \$726 of Convertible Notes
13-Mar-14	7,643,300	7,643,300	\$0.000100	\$764	Redemption of \$764 of Convertible Notes
20-Mar-14	8,043,450	8,043,450	\$0.000100	\$804	Redemption of \$804 of Convertible Notes
31-Mar-14	8,027,206	8,027,206	\$0.000100	\$803	Redemption of \$803 of Convertible Notes
01-Apr-14	8,043,450	8,043,450	\$0.000100	\$804	Redemption of \$804 of Convertible Notes
14-Apr-14	8,870,000	8,870,000	\$0.000100	\$887	Redemption of \$887 of Convertible Notes
18-Apr-14	9,333,900	9,333,900	\$0.000100	\$933	Redemption of \$933 of Convertible Notes
22-Apr-14	9,333,900	9,333,900	\$0.000100	\$933	Redemption of \$933 of Convertible Notes
22-Apr-14	10,000,000	10,000,000	\$0.000100	\$1,000	Redemption of \$1,000 of Convertible Notes
24-Apr-14	10,000,000	10,000,000	\$0.001000	\$10,000	Redemption of \$10,000 of Convertible Notes
06-May-14	10,000,000	10,000,000	\$0.000100	\$1,000	Redemption of \$1,000 of Convertible Notes
06-May-14	10,000,000	10,000,000	\$0.000100	\$1,000	Redemption of \$1,000 of Convertible Notes
06-May-14	10,000,000	10,000,000	\$0.000077	\$767	Redemption of \$767 of Convertible Notes
07-May-14	10,000,000	10,000,000	\$0.000100	\$1,000	Redemption of \$1,000 of Convertible Notes

08-May-14	9,400,000	9,400,000	\$0.000100	\$940	Redemption of \$940 of Convertible Notes
08-May-14	10,000,000	10,000,000	\$0.000100	\$1,000	Conversion of 10,000 Series E Preferred stock
09-May-14	10,800,000	10,800,000	\$0.000100	\$1,080	Redemption of \$1,080 of Convertible Notes
19-May-14	10,800,000	10,800,000	\$0.000100	\$1,080	Redemption of \$1,080 of Convertible Notes
21-May-14	11,370,450	11,370,450	\$0.000100	\$1,137	Redemption of \$1,137 of Convertible Notes
23-May-14	11,370,450	11,370,450	\$0.000100	\$1,137	Redemption of \$1,137 of Convertible Notes
28-May-14	10,000,000	10,000,000	\$0.000100	\$1,000	Redemption of \$1,000 of Convertible Notes
03-Jun-14	14,488,000	14,488,000	\$0.000100	\$1,449	Redemption of \$1,449 of Convertible Notes
03-Jun-14	14,500,000	14,500,000	\$0.000100	\$1,450	Redemption of \$1,450 of Convertible Notes
09-Jun-14	20,000,000	20,000,000	\$0.001000	\$20,000	Redemption of \$20,000 of Convertible Notes
10-Jun-14	18,800,000	18,800,000	\$0.000100	\$1,880	Redemption of \$1,880 of Convertible Notes
12-Jun-14	18,838,000	18,838,000	\$0.000100	\$1,884	Redemption of \$1,884 of Convertible Notes
18-Jun-14	19,800,000	19,800,000	\$0.000100	\$1,980	Redemption of \$1,980 of Convertible Notes
25-Jun-14	20,860,600	20,860,600	\$0.000100	\$2,086	Redemption of \$2,086 of Convertible Notes
26-Jun-14	21,900,000	21,900,000	\$0.000100	\$2,190	Redemption of \$2,190 of Convertible Notes

479,741,545

Private offering stockholder information:

Date	Holding	Current %	Stockholder	Beneficial owner or Controller
28-Mar-12	10,000,000		Nejo Ltd	
	10,000,000		P Casey	
	10,000,000		G Green	
	1,000,000		I Shaw	
	6,900,000		Anchor Financial	
	6,200,000		Tiffany Asset Group	
	4,900,000		Alpha Brilliant	
	5,000,000		Kars Capital	
	5,960,000		E Sexsmith	
	5,500,000		Macau Consultants	
	5,000,000		Convergent Capital	
	5,800,000		Tower Financial	
01-Mar-13	4,100,000		Freeport Securities	
	4,200,000		Windsong Investments	
07-Mar-13	250,000		Macca Holdings	
	1,250,000		M Bergman	
	1,250,000		Kaufman Associates	
25-Apr-13	500,000		Macca Holdings	
	750,000		Greenwich Financial	
20-Jun-13	2,000,000		Macca Holdings	
25-Jun-13	2,000,000		iNet Holdings	
09-Aug-13	1,000,000		Greenwich Financial	
	1,200,000		Joseph Fragala	
13-Aug-13	750,000		iNet Holdigns LLC	
16-Aug-13	750,000		Macca Holdings LLC	
03-Sep-13	8,250,000		iNet Holdigns LLC	
10-Sep-13	5,000,000		Appinero LLC	
11-Feb-14	6,240,000	36%	Redwood Management	Gary Rogers and John Denobile, 16850 Collins Ave # # 112-341, Sunny Isles, Florida 33160
14-Feb-14	6,563,800		Redwood Management	
25-Feb-14	6,907,680		Redwood Management	
05-Mar-14	7,260,000		Redwood Management	
13-Mar-14	7,643,300		Redwood Management	
20-Mar-14	8,043,450		Redwood Management	
31-Mar-14	8,027,206	20%	Bou Trust	Alan Uryniak (Trustee), 9 Wayne Street, Montvale, New Jersey 07645
01-Apr-14	8,043,450		Redwood Management	
14-Apr-14	8,870,000		Redwood Management	

18-Apr-14	9,333,900	Bou Trust
22-Apr-14	9,333,900	Redwood Management
	10,000,000	Alpha Brilliant Limited
24-Apr-14	10,000,000	Gold Coast Capital Inc
06-May-14	10,000,000	Freeport Securities
	10,000,000	Theman Holdings Inc
	10,000,000	Windsong Investments LTD
07-May-14	10,000,000	Anchor Financial Inc
08-May-14	9,400,000	Redwood Management
	10,000,000	Standard Trade Inc
09-May-14	10,800,000	Bou Trust
19-May-14	10,800,000	Redwood Management
21-May-14	11,370,450	Bou Trust
23-May-14	11,370,450	Redwood Management
28-May-14	10,000,000	Gold Coast Capital Inc
03-Jun-14	14,488,000	Redwood Management
	14,500,000	Bou Trust
09-Jun-14	20,000,000	Nobilis Consulting
10-Jun-14	18,800,000	Redwood Management
12-Jun-14	18,838,000	Bou Trust
18-Jun-14	19,800,000	Redwood Management
25-Jun-14	20,860,600	Redwood Management
26-Jun-14	21,900,000	Bou Trust

478,704,186

Redwood Management LLC, BOU Trust, Alpha Brilliant, Anchor Financial, Freeport Securities, Tower Financial and Windsong Investments all hold reserve options on Common Stock purchased through the redemption of Convertible Notes. As at June 30, 2014 their reserve accounts and stock draw-downs were as follows:

	Options	Converted	Balance
Alpha Brilliant	100,000,000	10,000,000	90,000,000
Anchor Financial	100,000,000	10,000,000	90,000,000
BOU Trust	250,000,000	94,769,556	155,230,444
Freeport Securities	100,000,000	10,000,000	90,000,000
Redwood Mgmt	300,000,000	174,424,630	125,575,370
Tower Financial	100,000,000	-	100,000,000
Windsong Inv	40,000,000	10,000,000	30,000,000
Total	990,000,000	309,194,186	680,805,814 C

All stockholdings relate to purchases and transfers registered with our Transfer Agents up to and including June 30, 2014.

Reserved and Available Stocks:

Authorized at June 30, 2014 500,000,000 A

Issued and Outstanding:

By Reserves 309,194,186

By Others 170,547,359

479,741,545 B

Available at June 30, 2014 (A-B) 20,258,455

Balance available to Reserves (680,805,814) C

Increase in Authorized Stock July 01, 2014 1,000,000,000

Available at July 01, 2014 339,452,641

E. The price at which the shares were offered, and the amount actually paid to the issuer;

See Note D

F. The trading status of the shares; and

All shares are fully tradeable and unencumbered

G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

All shares were issued without restriction or legend

With respect to private offerings of securities, the list shall also indicate the identity of the persons who purchased securities in such private offering; *provided, however*, that in the event that any such person is an entity, the list shall also indicate (a) the identity of each natural person beneficially owning, directly or indirectly, more than ten percent (10%) of any class of equity securities of such entity and (b) to the extent not otherwise disclosed, the identity of each natural person who controlled or directed, directly or indirectly, the purchase of such securities for such entity.

5) Financial Statements

Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualification for the OTC Pink Current Information tier. For the initial disclosure statement (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.

- A. Balance sheet;
- B. Statement of income;
- C. Statement of cash flows;
- D. Financial notes; and
- E. Audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with US GAAP by persons with sufficient financial skills.

You may either (i) attach/append the financial statements to this disclosure statement or (ii) post such financial statements through the OTC Disclosure & News Service as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial reports separately as described in part (ii) above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to otcq.com in the field below.

Interim Report to June 30, 2014

Information contained in a Financial Report is considered current until the due date for the subsequent Financial Report. To remain in the OTC Pink Current Information tier, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of its fiscal quarter-end date.

6) Describe the Issuer's Business, Products and Services

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

- A. a description of the issuer's business operations;

The Company's business operations consist of doing business in the cell repair and cell replacement for Equine stock only at present, but we are pursuing FDA approval for existing and modified products to be used for the repair of the Human Body. Its products have been successfully utilised for the repair of horses tendons and have the added bonus of being patented worldwide, with an exclusive licence in the name of the Company for equine and human

applications. In October 2013 we had to cease trialing the process due to lack of available and sustainable funds. The new initiative to generate investment into the company will allow us to recommence these trials and move towards selling the equine product on the open market. As a result, the Company is still in development and approval stage. We are looking to raise the estimated \$2million required to obtain US Food and Drug Administration approval of the patented process for humans and to make the product available to our targeted markets. This process has continued and has found some success following the release into the market of converted stocks. Interest in our shares has been encouraging with the conversion of a large portion of our long-term debt into Common Stock which has in turn necessitated our increasing the authorized capital of the Company. Although we are still short of our targetted investment level which would allow trials to recommence, we will be looking to take advantage of the market activity by issuing new shares in the near future as well as developing other long-term investment possibilities.

B. Date and State (or Jurisdiction) of Incorporation:

05/20/2011 domiciled to the State of Wyoming

C. the issuer's primary and secondary SIC Codes;

Primary SIC Code: 5094; Secondary SIC Code: None

D. the issuer's fiscal year end date;

31st December

E. principal products or services, and their markets;

The Company's principal product relates to existing patent licences held for cell repair and cell replacement of Equine stock. The main markets for the current product are working and sporting horse stock.

7) Describe the Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

None

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Susan Allwork - Director

John Meredith - President, CEO, CFO/Treasurer

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

Redwood Management of 16850 Collins Ave. Ste 112-341, Sunny Isles, Florida 33160.

Controlling members of Redwood Management are Gary Rogers and John Denobile of the same address.

Redwood Management controls 174,424,630 Common Stock = 36%

BOU Trust of 9 Wayne Street, Montvale, New Jersey 07645.

Controlling trustee of BOU Trust is Alan Uryniak of the same address. BOU Trust controls 94,769,556 Common Stock = 20%

No other individual controls more than 10% of the Company's equity

9) **Third Party Providers**

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel

Name: Lorin A Rosen

Firm: LARLaw Group PC

Address 1: 6 Butler Court, Centereach

Address 2: New York 11720

Phone: 877-570-2620

Email: _____

Accountant or Auditor

Name: None

Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Investor Relations Consultant

Name: None
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Other Advisor: Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement.

Name: None
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

The certifications shall follow the format below:

I, Susan Allwork certify that:

1. I have reviewed this Interim Report OTC disclosure statement for the quarter ending June 30, 2014t of Therapy Cells, Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 20, 2014 [Date]

/s/Susan Allwork [Signature]
(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Director
[Title]

I, John Meredith certify that:

1. I have reviewed this Interim statement of Therapy Cells, Inc;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 20, 2014 [Date]

/s/John Meredith [Signature]

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)

Director

[Title]